% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:849952,
      author       = {Galldiks, Norbert and Dunkl, Veronika and Ceccon, Garry and
                      Tscherpel, Caroline and Stoffels, Gabriele and Law, Ian and
                      Henriksen, Otto M. and Muhic, Aida and Poulsen, Hans S. and
                      Steger, Jan and Bauer, Elena K. and Lohmann, Philipp and
                      Schmidt, Matthias and Shah, Nadim J. and Fink, Gereon R. and
                      Langen, Karl-Josef},
      title        = {{E}arly treatment response evaluation using {FET} {PET}
                      compared to {MRI} in glioblastoma patients at first
                      progression treated with bevacizumab plus lomustine},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {45},
      number       = {13},
      issn         = {0340-6997},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {FZJ-2018-04047},
      pages        = {2377–2386},
      year         = {2018},
      abstract     = {BackgroundThe goal of this prospective study was to compare
                      the value of both conventional MRI and
                      O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET for response
                      evaluation in glioblastoma patients treated with bevacizumab
                      plus lomustine (BEV/LOM) at first progression.MethodsAfter
                      chemoradiation with concomitant and adjuvant temozolomide,
                      21 IDH wild-type glioblastoma patients at first progression
                      (age range, 33–75 years; MGMT promoter unmethylated,
                      $81\%)$ were treated with BEV/LOM. Contrast-enhanced MRI and
                      FET-PET scans were performed at baseline and after 8–10
                      weeks. We obtained FET metabolic tumor volumes (MTV) and
                      tumor/brain ratios. Threshold values of FET-PET parameters
                      for treatment response were established by ROC analyses
                      using the post-progression overall survival (OS) ≤/>9
                      months as the reference. MRI response assessment was based
                      on RANO criteria. The predictive ability of FET-PET
                      thresholds and MRI changes on early response assessment was
                      evaluated subsequently concerning OS using uni- and
                      multivariate survival estimates.ResultsEarly treatment
                      response as assessed by RANO criteria was not predictive for
                      an OS>9 months (P = 0.203), whereas relative reductions
                      of all FET-PET parameters significantly predicted an OS>9
                      months (P < 0.05). The absolute MTV at follow-up enabled
                      the most significant OS prediction (sensitivity, $85\%;$
                      specificity, $88\%;$ P = 0.001). Patients with an
                      absolute MTV below 5 ml at follow-up survived significantly
                      longer (12 vs. 6 months, P < 0.001), whereas early
                      responders defined by RANO criteria lived only
                      insignificantly longer (9 vs. 6 months; P = 0.072). The
                      absolute MTV at follow-up remained significant in the
                      multivariate survival analysis
                      (P = 0.006).ConclusionsFET-PET appears to be useful for
                      identifying responders to BEV/LOM early after treatment
                      initiation.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29982845},
      UT           = {WOS:000450713500016},
      doi          = {10.1007/s00259-018-4082-4},
      url          = {https://juser.fz-juelich.de/record/849952},
}